AveXis Reports First Quarter 2018 Financial and Operating Results
May 03, 2018 16:01 ET
|
AveXis, Inc.
-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be held in June 2018 --...
AveXis Provides Update on Proposed Acquisition by Novartis AG
May 01, 2018 01:07 ET
|
AveXis, Inc.
CHICAGO, May 01, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
April 25, 2018 08:00 ET
|
AveXis, Inc.
CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
April 24, 2018 16:01 ET
|
AveXis, Inc.
– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial were...
AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
April 19, 2018 08:00 ET
|
AveXis, Inc.
CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion
April 09, 2018 00:45 ET
|
AveXis, Inc.
Novartis to acquire AveXis for $218 per share in cash AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader Transaction expected...
AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
March 27, 2018 08:05 ET
|
AveXis, Inc.
CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...
AveXis Enters into Licensing Agreement with Genethon
March 13, 2018 16:01 ET
|
AveXis, Inc.; Genethon
CHICAGO and ÉVRY, France , March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today announced they have entered into an exclusive, worldwide license agreement for in...
AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
February 27, 2018 16:01 ET
|
AveXis, Inc.
– On track to request pre-BLA meeting with FDA in Q2 2018 –– Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of 2018 – –...
AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
February 20, 2018 08:00 ET
|
AveXis, Inc.
CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological...